AstraZeneca (LON:AZN) received a GBX 7,100 ($92.77) target price from investment analysts at JPMorgan Chase & Co. in a report released on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 13.76% from the stock’s current price.
AZN has been the topic of a number of other reports. Barclays restated an “overweight” rating on shares of AstraZeneca in a research note on Monday, January 21st. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Tuesday, January 1st. Societe Generale upped their target price on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a “buy” rating in a research note on Wednesday, January 16th. Cfra set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Friday, November 9th. Finally, Credit Suisse Group reiterated an “outperform” rating on shares of AstraZeneca in a research note on Monday, October 29th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca presently has an average rating of “Buy” and a consensus price target of GBX 6,222.20 ($81.30).
Shares of AZN stock opened at GBX 6,241 ($81.55) on Thursday. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: QQQ ETF
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.